Haleon
✦ Quant Fair Value how this is computed
- Implied fair-value range of 9.50-14.08, from this stock's own trailing 5-year average P/E applied to trailing EPS.
- Current price is -23.1% below the average-multiple fair value of 11.79.
Valuation each multiple against its own 5-year range
Vs. peers Drug Manufacturers - Specialty & Generic
| Company | Market cap | P/E (TTM)i | P/Bi | Div yieldi |
|---|---|---|---|---|
| Haleon (HLN) | 39.76B | 19.14 | 1.85 | 2.09% |
| Takeda Pharmaceutical (TAK) | 69.76B | 311.00 | 1.50 | 1.44% |
| Teva Pharmaceutical Industries (TEVA) | 45.77B | 91.23 | 5.74 | 0.00% |
| Zoetis (ZTS) | 32.14B | 13.34 | 9.73 | 2.64% |
| United Therapeutics (UTHR) | 23.63B | 20.94 | 3.76 | 0.00% |
| Viatris (VTRS) | 22.50B | -37.04 | 1.64 | 2.45% |
Other StockVane-tracked companies in the same industry.
Morningstar
Trading 7.2% below Morningstar's fair value estimate.
Fair value
Haleon PLC is assigned a 5-star quantitative star rating, reflecting our opinion that this share class offers a compelling opportunity for investors. The stock currently trades at a 7% discount to our quantitative fair value estimate of $9.73 per share, which is reinforced by this estimate's low uncertainty rating.
The company's liquidity increases our quantitative valuation. Adequate liquidity allows a company to meet short-term obligations, enhancing financial stability and reducing distress risk. For example, the firm's median trading volume over the past 60 days falls in the top 10% globally. Trading volumes are high on shares, which may indicate increased institutional interest in stock ownership. We believe this is a sign that shares could be undervalued.
Alternatively, the firm's balance sheet is potentially concerning. Excessive leverage heightens financial risk, potentially undermining a firm's value. The firm's EBITDA/interest coverage ratio of 8.5, for example, falls in the bottom 40% compared with global peers. This gives us pause, as it can be a warning sign of financial distress if conditions don't improve. Despite our favorable price/fair value ratio, this characteristic is a negative attribute.
Economic moat
The company earns a quantitative moat rating of wide, suggesting a strong ability to maintain superior profitability thanks to competitive advantages that could persist up to two decades. In addition, the company's moderate financial health score is decent and doesn't seriously concern us with regard to financial distress.
By Quantitative Equity Report
Quote time 2026-11-20 19:59:23 · For reference only, not investment advice and not tailored to your situation.
Haleon discussion 0 comments